Systemic rituximab for the treatment of the indolent forms of primary cutaneous B-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry

Muniesa, Cristina; Domingo‐Domenech, Eva; Fornons-Servent, Rosa; Peñate, Yeray; Estrach, M.T.; Ramón, M.; Medina, Susana; Flórez, Ángeles; Ortiz‐Romero, Pablo L.; Sánchez-Caminero, M.P.; Torres‐Navarro, Ignacio; Acebo, Elvira; Yanguas, I.; Fernández-de-Misa, Ricardo; Blanes, Mar; Zayas, Ana; Descalzo, M.Á.; García‐Doval, I.; Servitje, Octavio

doi:10.1016/j.jaad.2020.07.028

Cited by 4 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11 In indolent subtypes, studies have shown that both intralesional and systemic rituximab are safe and effective treatment options. 12,13 Overall, these results suggest that rituximab is an effective method of treatment and should be considered early in patients with PCBCL, regardless of type.…”

Section: Discussionmentioning

confidence: 75%

“…Multiple studies have highlighted the importance of rituximab in the treatment of PCDLBCL‐LT, including a 2014 French study that showed that its inclusion in therapy led to a doubling of survival rates compared to regimens without it 11 . In indolent subtypes, studies have shown that both intralesional and systemic rituximab are safe and effective treatment options 12,13 . Overall, these results suggest that rituximab is an effective method of treatment and should be considered early in patients with PCBCL, regardless of type.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Intralesional and systemic rituximab in the treatment of primary cutaneous B‐cell lymphoma

Besch‐Stokes,

Shahin,

Bhullar

et al. 2023

JEADV Clinical Practice

View full text Add to dashboard Cite

BackgroundPrimary cutaneous B‐cell lymphoma (PCBCL) is a group of B‐cell lymphomas of the skin containing primary cutaneous follicle centre lymphoma (PCFCL) and marginal zone B‐cell lymphoma/lymphoproliferative disorder (PCMZL), which are indolent, and diffuse large B‐cell lymphoma, leg type (PCDLBCL‐LT), which is aggressive.ObjectivesTo evaluate treatment outcomes between PCBCL subtypes after treatment with rituximab and to compare the efficacy of intralesional against systemic rituximab in indolent subtypes.MethodsA search for patients diagnosed with PCBCL and treated with rituximab (systemic or intralesional) across all Mayo Clinic sites was performed, yielding 39 patients.ResultsEight patients had PCFCL (six treated intralesionally and two systemically), 11 had PCMZL (four intralesional, eight systemic with one dual‐treated) and 20 had PCDLBCL‐LT (all systemic). The average age at diagnosis was 62.1 years (SD = 15.1), with average follow‐up of 1852.6 days (SD = 1473.2). 69.2% of all patients treated with any form of rituximab experienced a complete response (100% PCFCL, 81.8% PCMZL and 50% PCDLBCL‐LT). When comparing all three subtypes, a significant difference was seen in overall treatment response (p = 0.022), and progressive disease rates (p = 0.015), but not in retreatment with rituximab (p = 0.440), time to retreatment (p = 0.757), recurrence (p = 0.907) or survival (p = 0.093). In the indolent subtypes, no difference in overall treatment response (p = 1.000), progressive disease rates (p = 1.000), recurrence (p = 0.650), rituximab retreatment (p = 0.650) or time to retreatment (p = 0.724) was observed.ConclusionsThis study suggests that rituximab, as systemic therapy and intralesional therapy, is effective in the management of PCBCL, and that intralesional therapy should be considered before more aggressive therapy in indolent disease.

show abstract

Section: Discussionmentioning

confidence: 75%

Section: Discussionmentioning

confidence: 99%